Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CCR4 | P51679 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038976 | 0.90 | CCR4 (0.50) | CCR4CYP1A2CYP3A4CYP2C19SCN9A | |
| SCHEMBL6038894 | 0.88 | CCR4 (0.49) | CCR4SCN9AMAPTKDM4EALDH1A1 | |
| SCHEMBL6038834 | 0.88 | CCR4 (0.44) | CYP19A1CCR4SCN9AMAPTKDM4E | |
| SCHEMBL6038463 | 0.87 | CCR4 (0.48) | CCR4SCN9AMAPTKDM4EALDH1A1 | |
| SCHEMBL6038593 | 0.87 | CCR4 (0.48) | CCR4SCN9AMAPTKDM4EALDH1A1 | |
| SCHEMBL6038816 | 0.87 | CCR4 (0.50) | CCR4SCN9AMAPTKDM4EALDH1A1 | |
| SCHEMBL6038813 | 0.87 | CCR4 (0.52) | CCR4SCN9AMAPTKDM4EALDH1A1 | |
| SCHEMBL6038792 | 0.87 | CCR4 (0.47) | CCR4CYP1A2CYP3A4CYP2C19SCN9A | |
| SCHEMBL6038422 | 0.86 | CCR4 (0.47) | CCR4SCN9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6039093 | 0.86 | CCR4 (0.47) | CCR4SCN9AMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | KMO 1139/4885CYP19A1 3606/4885CCR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.